The human eye is a highly complex organ comprised of multiple tissue types, layers, and components that must work perfectly in sync and be constantly maintained. The retina of the eye is especially vulnerable to oxidative damage because it is one of the highest oxygen-consuming tissues of the body and experiences some of the greatest production of ROS. Antioxidants, especially carotenoids, are a first-line defense against the attack on our eyes.
Algatech, a leading astaxanthin manufacturer, developed AstaPure® EyeQ, a high-purity powder derived from Haematococcus pluvialis microalgae — the richest known source of natural astaxanthin — with improved bioavailability. It is a microencapsulated, cold water-soluble 2% natural astaxanthin powder, it has no flavor or aroma, and is suitable for targeted health beverages, as a shot delivery format, in premix drinks, or dispenser caps. Or, it can be readily incorporated into supplements (from softgels to gummies and other chewables) and functional foods, such as bars. It also is Kosher and Halal, non-GMO, cleanlabel, sustainable, and minimally processed ingredient. The astaxanthin is encapsulated using an innovative, patented microencapsulation technology, with a unique formula of completely biodegradable and natural materials and protein, enabling higher bioavailability in the eyes and brain.
Our eyes are constantly besieged by air, allergens, fatigue, light (especially from computer and smart device screens), and other insults. Moreover, eye fatigue has become epidemic due to VDT Syndrome, a term used to describe daily video display terminal exposure that severely exacerbates the symptoms of eye fatigue. These lead to oxidative stress that damages DNA and cellular bodies via reactive oxygen species (ROS) such as “free radicals.” Studies show that Astaxanthin intercepts oxygen radicals and helps support other antioxidants to promote detoxification, protecting the eyes from damage, and also helps boost acuity of vision.
A clinical study conducted in 2018 by Algatech and principal investigator Rafael Bitzur, MD, former Secretary of the Israeli Society for the Treatment and Prevention of Atherosclerosis at the Lipids Clinic, Sheba Medical Center, Israel, demonstrates that AstaPure® EyeQ delivers a two-fold increase in bioavailability over standard astaxanthin supplements in the plasma of healthy volunteers. A following preclinical study conducted by principal investigator Tatsuya Sugawara, PhD, of the Graduate School of Agriculture, Kyoto University, Japan, shows that AstaPure® EyeQ reaches the plasma and crosses both the blood-brain and the blood-retinabarriers, hence reaches the brain and eyes.